Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
By D. McGuire, W. Shih, F. Cosentino, B. Charbonnel, D. Cherney, S. Dagogo-Jack, R. Pratley, Michelle Greenberg, Shuai Wang, S. Huyck and 4 more. JAMA cardiology, 2020
961 citations recorded by the source corpus.
This meta-analysis uses data from patients with type 2 diabetes from 6 outcomes trials to investigate the association of sodium-glucose cotransporter 2 inhibitors with cardiovascular- and kidney disease–related outcomes.
Subfields: Endocrinology, Diabetes and Metabolism, Nephrology, Surgery
View Paper: https://www.semanticscholar.org/paper/bc2407ac13b474cd804d5f314983bb85a96b823f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association (2023, background): “153 SGLT2 inhibitors are expected to have the greatest absolute reduction in HF events in those with diabetes and subclinical cardiac dysfunction given their high baseline HF risk.”
- Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association (2023, background): “115 These agents should be prioritized in patients with type 2 diabetes and stage B HF given their high absolute HF risk.”
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022, positive): “Conversely, SGLT2i, albeit reducing cardiovascular death, had a neutral effect on stroke [142, 255].”
- Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (2022, methodology): “Pairwise meta-analyses of SGLT2i CVOTs verified that SGLT2i reduced MACE, HHF, and a composite kidney outcome in the overall population versus placebo (142,249).”